Is 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid? Is 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid safe for nursing mother and child? Does 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid extracts into breast milk? Does 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid has any long term or short term side effects on infants? Can 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid influence milk supply or can 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid decrease milk supply in lactating mothers?

It is excreted in breast milk in clinically non-significant amount and no problems have been observed in infants whose mothers took this medication. Levels in plasma and urine of such infants were undetectable. Having published less quantity of studies than with other drugs of the same group, safer alternatives may be preferable, especially in the neonatal period and in case of prematurity. The American Academy of Pediatrics rates it as usually compatible with breastfeeding.

Low amounts of 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid in milk and failure to detect 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid or its metabolites in the urine of 2 older infants indicates that it would not be expected to cause adverse effects in older breastfed infants. Because there is no published experience with 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid during breastfeeding in the newborn period, shorter-acting agents may be preferred while nursing a newborn or preterm infant.

No adverse effects were found in the breastfed infant of a patient receiving 20 mg of 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid daily for 4 months starting the 9th month postpartum.[1]Four infants 3 to 4.5 months of age remained healthy during long-term therapy of their mothers with 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid 20 mg daily.[2]